{
  "actions": [
    {
      "acted_at": "2022-04-05",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2022-04-05",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    },
    {
      "acted_at": "2022-04-05",
      "action_code": "H11100",
      "committees": [
        "HSWM"
      ],
      "references": [],
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    },
    {
      "acted_at": "2022-04-06",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr7400-117",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "14"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Ways and Means",
      "committee_id": "HSWM"
    }
  ],
  "congress": "117",
  "cosponsors": [
    {
      "bioguide_id": "M001190",
      "district": "2",
      "name": "Mullin, Markwayne",
      "original_cosponsor": true,
      "sponsored_at": "2022-04-05",
      "state": "OK",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2022-04-05",
  "number": "7400",
  "official_title": "To direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States.",
  "popular_title": null,
  "related_bills": [
    {
      "bill_id": "s3991-117",
      "identified_by": "CRS",
      "reason": "identical",
      "type": "bill"
    }
  ],
  "short_title": "American Made Pharmaceuticals Act of 2022",
  "sponsor": {
    "bioguide_id": "C001119",
    "district": "2",
    "name": "Craig, Angie",
    "state": "MN",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2022-04-05",
  "subjects": [
    "Buy American requirements",
    "Child health",
    "Congressional oversight",
    "Drug therapy",
    "Emergency medical services and trauma care",
    "Health",
    "Health care costs and insurance",
    "Health technology, devices, supplies",
    "Infectious and parasitic diseases",
    "Manufacturing",
    "Medicaid",
    "Medicare",
    "Poverty and welfare assistance",
    "Prescription drugs",
    "Public contracts and procurement"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2022-04-05",
    "date": "2022-09-14T15:30:17Z",
    "text": "American Made Pharmaceuticals Act of 2022\n\nThis bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).\n\nThe program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "American Made Pharmaceuticals Act of 2022",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "American Made Pharmaceuticals Act of 2022",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States.",
      "type": "official"
    }
  ],
  "updated_at": "2022-12-29T23:03:26Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/117/hr/BILLSTATUS-117hr7400.xml"
}